Globus Medical, Inc. (GMED)
USD 81.78
(-1.97%)
USD 81.78
(-1.97%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 887.16 Million USD | 56.53% |
| 2022 | 522.86 Million USD | -0.22% |
| 2021 | 524.02 Million USD | 14.89% |
| 2020 | 456.1 Million USD | 6.41% |
| 2019 | 428.63 Million USD | 13.8% |
| 2018 | 376.67 Million USD | 17.93% |
| 2017 | 319.4 Million USD | 18.23% |
| 2016 | 270.16 Million USD | 7.64% |
| 2015 | 250.99 Million USD | 14.36% |
| 2014 | 219.48 Million USD | 4.82% |
| 2013 | 209.38 Million USD | 6.4% |
| 2012 | 196.78 Million USD | 20.1% |
| 2011 | 163.85 Million USD | 13.87% |
| 2010 | 143.89 Million USD | 11.6% |
| 2009 | 128.94 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 293.37 Million USD | -9.76% |
| 2024 Q3 | 276.11 Million USD | 0.11% |
| 2024 Q2 | 275.81 Million USD | -5.99% |
| 2023 Q4 | 325.09 Million USD | 63.12% |
| 2023 FY | 818.45 Million USD | 56.53% |
| 2023 Q1 | 148.09 Million USD | 4.23% |
| 2023 Q2 | 145.96 Million USD | -1.44% |
| 2023 Q3 | 199.29 Million USD | 36.54% |
| 2022 Q2 | 128.5 Million USD | 4.76% |
| 2022 Q4 | 142.08 Million USD | 9.63% |
| 2022 Q3 | 129.6 Million USD | 0.85% |
| 2022 FY | 522.86 Million USD | -0.22% |
| 2022 Q1 | 122.67 Million USD | -24.34% |
| 2021 Q2 | 127.42 Million USD | 8.36% |
| 2021 Q4 | 162.13 Million USD | 38.73% |
| 2021 FY | 524.02 Million USD | 14.89% |
| 2021 Q1 | 117.58 Million USD | 4.92% |
| 2021 Q3 | 116.87 Million USD | -8.28% |
| 2020 Q1 | 112.71 Million USD | 1.52% |
| 2020 FY | 456.1 Million USD | 6.41% |
| 2020 Q4 | 112.07 Million USD | 4.04% |
| 2020 Q3 | 107.72 Million USD | -12.84% |
| 2020 Q2 | 123.58 Million USD | 9.65% |
| 2019 Q3 | 106.58 Million USD | -0.92% |
| 2019 FY | 428.63 Million USD | 13.8% |
| 2019 Q1 | 103.45 Million USD | 2.97% |
| 2019 Q2 | 107.57 Million USD | 3.99% |
| 2019 Q4 | 111.03 Million USD | 4.17% |
| 2018 FY | 376.67 Million USD | 17.93% |
| 2018 Q4 | 100.46 Million USD | 8.24% |
| 2018 Q2 | 92.82 Million USD | 2.49% |
| 2018 Q1 | 90.57 Million USD | 4.57% |
| 2018 Q3 | 92.81 Million USD | -0.01% |
| 2017 Q1 | 79.5 Million USD | 4.22% |
| 2017 Q2 | 76.96 Million USD | -3.2% |
| 2017 Q3 | 76.32 Million USD | -0.82% |
| 2017 FY | 319.4 Million USD | 18.23% |
| 2017 Q4 | 86.6 Million USD | 13.47% |
| 2016 Q1 | 64.76 Million USD | 2.44% |
| 2016 Q3 | 65.35 Million USD | 2.67% |
| 2016 Q2 | 63.65 Million USD | -1.71% |
| 2016 Q4 | 76.28 Million USD | 16.73% |
| 2016 FY | 270.16 Million USD | 7.64% |
| 2015 Q1 | 60.94 Million USD | 8.61% |
| 2015 Q2 | 63.58 Million USD | 4.34% |
| 2015 Q3 | 63.23 Million USD | -0.55% |
| 2015 Q4 | 63.22 Million USD | -0.02% |
| 2015 FY | 250.99 Million USD | 14.36% |
| 2014 Q2 | 54.11 Million USD | -0.0% |
| 2014 Q4 | 56.11 Million USD | 1.78% |
| 2014 Q3 | 55.13 Million USD | 1.87% |
| 2014 Q1 | 54.12 Million USD | 3.91% |
| 2014 FY | 219.48 Million USD | 4.82% |
| 2013 FY | 209.38 Million USD | 6.4% |
| 2013 Q3 | 52.27 Million USD | -0.98% |
| 2013 Q4 | 52.08 Million USD | -0.35% |
| 2013 Q1 | 52.24 Million USD | 0.75% |
| 2013 Q2 | 52.78 Million USD | 1.04% |
| 2012 Q1 | 47.96 Million USD | 10.7% |
| 2012 FY | 196.78 Million USD | 20.1% |
| 2012 Q4 | 51.85 Million USD | 6.19% |
| 2012 Q3 | 48.83 Million USD | 3.82% |
| 2012 Q2 | 47.03 Million USD | -1.93% |
| 2011 Q4 | 43.32 Million USD | 6.71% |
| 2011 Q2 | 39.85 Million USD | -0.49% |
| 2011 FY | 163.85 Million USD | 13.87% |
| 2011 Q1 | 40.05 Million USD | 0.0% |
| 2011 Q3 | 40.6 Million USD | 1.86% |
| 2010 FY | 143.89 Million USD | 11.6% |
| 2009 FY | 128.94 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Abbott Laboratories | 15.71 Billion USD | 94.354% |
| Allurion Technologies Inc. | 120.57 Million USD | -635.774% |
| Artivion, Inc. | 223.43 Million USD | -297.057% |
| Avanos Medical, Inc. | 375.5 Million USD | -136.261% |
| Butterfly Network, Inc. | 162.46 Million USD | -446.059% |
| Butterfly Network, Inc. | 162.46 Million USD | -446.059% |
| Bio-Rad Laboratories, Inc. | 1.04 Billion USD | 15.311% |
| Boston Scientific Corporation | 7.47 Billion USD | 88.136% |
| Perspective Therapeutics, Inc. | 17.42 Million USD | -4991.013% |
| CONMED Corporation | 564.24 Million USD | -57.23% |
| Edwards Lifesciences Corporation | 3.09 Billion USD | 71.298% |
| Paragon 28, Inc. | 210.1 Million USD | -322.256% |
| Glaukos Corporation | 367.83 Million USD | -141.184% |
| Inspire Medical Systems, Inc. | 568.49 Million USD | -56.054% |
| Integer Holdings Corporation | 250.95 Million USD | -253.508% |
| Medtronic plc | 16.12 Billion USD | 94.5% |
| Nevro Corp. | 389.36 Million USD | -127.846% |
| Owlet, Inc. | 51.21 Million USD | -1632.092% |
| Penumbra, Inc. | 590.87 Million USD | -50.143% |
| Vicarious Surgical Inc. | 80.66 Million USD | -999.794% |
| Smith & Nephew plc | 3.46 Billion USD | 74.411% |
| Sonendo, Inc. | 68.46 Million USD | -1195.786% |
| STERIS plc | 1.4 Billion USD | 36.648% |
| Stryker Corporation | 9.2 Billion USD | 90.366% |
| Vapotherm, Inc. | 66.02 Million USD | -1243.673% |
| Zimmer Biomet Holdings, Inc. | 3.27 Billion USD | 72.919% |